fbpx

molecules of the month

JNJ-64619178

pseudo-irreversible methyltransferase inh.

oral, phase I, cancer

from adenosine derivative library + opt.

Molecular Cancer Therapeutics

Janssen R&D

Chemical structure of molecule JNJ-64619178
1 min read

The Janssen PRMT5 inhibitor, onametostat (JNJ-64619178) is a selective, orally active and pseudo-irreversible protein arginine methyltransferase 5 (PRMT5) inhibitor with high selectivity and potency (subnanomolar range, PRMT5-MEP-50 IC50=0.14 nM) under various conditions. While JNJ-64619178 binds non-covalently in the PRMT5 SAM and substrate-binding sites evidenced by co-crystallography (PDB: 6RLQ), the molecule has a long-residence time, leading to sustained inhibition of PRMT5 even after short compound exposure. Interestingly, PD was observed for 6 days after treatment cessation, and comparable efficacy was observed with continuous daily dosing as in 7 d on, 7 d off cycles. Since PRMT5-dependent methylation events are reversed only by turnover of substrate proteins rather than by demethylases and PRMT5 itself has a long half-life, PRMT5 inhibitors with a long residence time…


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: